US 11,939,591 B2
Genetically modified MSC and therapeutic methods
Jan Nolta, Davis, CA (US); Karen Pepper, Davis, CA (US); Fernando Fierro, Davis, CA (US); and Gerhard Bauer, Davis, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Feb. 5, 2021, as Appl. No. 17/168,645.
Application 17/168,645 is a continuation of application No. 16/153,211, filed on Oct. 5, 2018, granted, now 10,913,957.
Application 16/153,211 is a continuation of application No. 15/351,415, filed on Nov. 14, 2016, abandoned.
Application 15/351,415 is a continuation of application No. 13/844,138, filed on Mar. 15, 2013, abandoned.
Application 13/844,138 is a continuation in part of application No. PCT/US2012/053537, filed on Aug. 31, 2012.
Prior Publication US 2022/0002748 A1, Jan. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A01N 63/00 (2020.01); A61K 48/00 (2006.01); C12N 15/86 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 48/005 (2013.01); C12N 2740/15043 (2013.01)] 16 Claims
 
1. A viral packaging system comprising:
(a) a vector including a polynucleotide, the following operatively linked to each other: a MNDU3 promoter consisting essentially of nucleotides 285 to 844 of SEQ ID NO: 23; a nucleic acid encoding a 165A isoform VEGF protein, and a WPRE enhancer consisting essentially of nucleotides of 7564 to 8160 of SEQ ID NO: 23, or the complement of the polynucleotide;
(b) a packaging plasmid; and
(c) an envelope plasmid.